This month, the second wave of biosimilar Humira (adalimumab) sponsors ― as many as eight ― become free to launch their products. July also brings an end to Hikma’s six-month monopoly on generic competition to Jazz Pharmaceuticals’ Xyrem (sodium oxybate) 0.5g/ml oral solution in the US. Read on for additional generics highlights.

You can also download the PDF by clicking the button below

Related Resources

JUN 23, 2023

Generics Bulletin Explains: The Next Wave of US Humira Biosimilars

Generics Bulletin breaks down all the different Humira biosimilars players and how they are positioning themselves in such a competitive US market.

DEC 01, 2022

In Vivo Outlook 2023

Outlook 2023 includes exclusive interviews and features on topics that reach across the life sciences.

MAR 01, 2023

Q2 2023 Pharma Outlook Report

In this report, we cover catalysts from 24 drugs, devices, diagnostics, and deals expected to occur in Q2 2023.